References
- Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI. et al. 2024. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 30(4):1013–2. doi: 10.1038/s41591-024-02851-9.
- Català M, Mercadé-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, Rathod-Mistry T, Kostka K, Man WY, Delmestri A. et al. 2024. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 12(3):225–36. doi: 10.1016/S2213-2600(23)00414-9.
- Trinh NT, Jödicke AM, Català M, Mercadé-Besora N, Hayati S, Lupattelli A, Prieto-Alhambra D, Nordeng HM. 2024. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. Lancet Respir Med. 12(5):33–4. doi: 10.1016/S2213-2600(24)00082-1.
- Yousaf AR, Mak J, Gwynn L, Bloodworth R, Rai R, Jeddy Z, LB L, Edwards L, Olsho LEW, Newes-Adeyi G et al. 2023. COVID-19 mRNA vaccination reduces the occurrence of post-COVID conditions in U.S. Children aged 5–17 years following omicron SARS-CoV-2 infection, July 2021–September 2022. Vol. 10, Open Forum Infect Dis; p. ofad500.2466.